Published online Feb 26, 2022. doi: 10.12998/wjcc.v10.i6.1852
Peer-review started: July 19, 2021
First decision: October 16, 2021
Revised: October 21, 2021
Accepted: January 19, 2022
Article in press: January 19, 2022
Published online: February 26, 2022
Processing time: 219 Days and 10 Hours
Several breast cancer studies have reported the use of adjuvant opioids with the paravertebral block (PVB) to improve outcomes. However, there is no level-1 evidence justifying its use.
To elucidate if the addition of opioids to PVB improves pain control in breast cancer surgery patients.
We conducted an electronic literature search across PubMed, Embase, Scopus, and Google Scholar databases up to October 20, 2020. Only randomized con
Six RCTs were included. Our meta-analysis indicated significantly reduced 24-h total analgesic consumption with the addition of opioids to PVB as compared to placebo [standardized mean difference (SMD) -1.57, 95% confidence interval (CI): -2.93, -0.21, I2 = 94%]. However, on subgroup analysis, the results were non-significant for studies using single PVB (SMD: -1.76, 95%CI: -3.65, 0.13 I2 = 95.09%) and studies using PVB infusion (SMD: -1.30, 95%CI: -4.26, 1.65, I2 = 95.49%). Analysis of single PVB studies indicated no significant difference in the time to first analgesic request between opioid and placebo groups (mean difference -11.28, 95%CI: -42.00, 19.43, I2 = 99.39%). Pain scores at 24 h were marginally lower in the opioid group (mean difference -1.10, 95%CI: -2.20, 0.00, I2 = 0%). There was no difference in the incidence of postoperative nausea and vomiting between the two groups.
Current evidence suggests a limited role of adjuvant opioids with PVB for breast cancer surgery patients. Further homogenous RCTs with a large sample size are needed to clarify the beneficial role of opioids with PVB.
Core Tip: The use of opioids as adjuvants for nerve blocks has been increasing. However, it is not clear if the addition of opioids to paravertebral block (PVB) improves outcomes for breast cancer surgery patients. In our first systematic review and meta-analysis, we pooled data from six randomized controlled trials assessing the role of adjuvant opioids for PVB in patients undergoing breast cancer surgery. Our results indicate that the addition of opioids to PVB has a limited role in reducing 24-h analgesic consumption, time to first analgesic request, and pain scores as compared to placebo. Further high-quality studies are required to strengthen the evidence.